Investigating intrinsic radiosensitivity biomarkers to peptide receptor radionuclide therapy with [177Lu]Lu-DOTATATE in a panel of cancer cell lines
- 1 May 2021
- journal article
- research article
- Published by Elsevier in Nuclear Medicine and Biology
- Vol. 96-97, 68-79
Abstract
No abstract availableKeywords
Funding Information
- Les Amis de l'Institut Bordet asbl
This publication has 58 references indexed in Scilit:
- Peptide receptor radionuclide therapy of neuroendocrine tumors with 90Y-DOTATOC: Is treatment response predictable by pre-therapeutic uptake of 68Ga-DOTATOC?Diagnostic and Interventional Imaging, 2014
- Induction of Anti-Tumor Immune Responses by Peptide Receptor Radionuclide Therapy with 177Lu-DOTATATE in a Murine Model of a Human Neuroendocrine TumorDiagnostics, 2013
- Functional features of cancer stem cells in melanoma cell linesCancer Cell International, 2013
- Oxidative Stress and Antioxidant DefenseWorld Allergy Organization Journal, 2012
- DNA damage signaling in response to double-strand breaks during mitosisJournal of Cell Biology, 2010
- Somatostatin receptor scintigraphy might be useful for detecting skeleton abnormalities in patients with multiple myeloma and plasmacytomaEuropean Journal of Nuclear Medicine and Molecular Imaging, 2009
- Glutathione: Overview of its protective roles, measurement, and biosynthesisMolecular Aspects of Medicine, 2009
- Mechanisms of Cell Death in Oxidative StressAntioxidants & Redox Signaling, 2007
- Quantified relationship between cellular radiosensitivity, DNA repair defects and chromatin relaxation: a study of 19 human tumour cell lines from different originRadiotherapy and Oncology, 2004
- Radiation Sensitivity, H2AX Phosphorylation, and Kinetics of Repair of DNA Strand Breaks in Irradiated Cervical Cancer Cell LinesCancer Research, 2004